The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

Angela Dispenzieri, Martha Lacy, Steven R. Zeldenrust, Suzanne R. Hayman, Shaji K Kumar, Susan M. Geyer, John A. Lust, Jacob B. Allred, Thomas Elmer Witzig, S Vincent Rajkumar, Philip R. Greipp, Stephen J Russell, Brian Kabat, Morie Gertz

Research output: Contribution to journalArticle

190 Citations (Scopus)

Abstract

Primary systemic amyloidosis (AL) is an incurable plasma cell disorder. Lenalidomide, especially in conjunction with dexamethasone, is highly active in patients with multiple myeloma. We studied the toxicity and efficacy of lenalidomide in patients with AL. Patients with symptomatic AL, a measurable plasma cell disorder, and adequate hematologic and renal reserve were eligible. Patients received single-agent lenalidomide. If there was no evidence of progression after 3 months or of hematologic response after 3 cycles, dexamethasone was added. Twenty-three patients were enrolled. Thirteen were previously treated. Organ involvement was cardiac (64%), renal (73%), hepatic (23%), and nerve (14%). Within the first 3 cycles of therapy, 10 patients discontinued treatment: 4 early deaths, 3 adverse events, and 3 other causes. With a median follow-up of 17 months, 10 patients responded to treatment. In these patients, responses included 9 hematologic, 4 renal, 2 cardiac, and 2 hepatic. All but one of the responders had dexamethasone added to their treatment program. The most common grade 3 or 4 adverse events at least possibly attributable to lenalidomide were neutropenia (45%), thrombocytopenia (27%), rash (18%), and fatigue (18%). In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.

Original languageEnglish (US)
Pages (from-to)465-470
Number of pages6
JournalBlood
Volume109
Issue number2
DOIs
StatePublished - Jan 15 2007

Fingerprint

Dexamethasone
Amyloidosis
Patient treatment
Plasmas
Plasma Cells
Kidney
Toxicity
Primary amyloidosis
lenalidomide
Fatigue of materials
Liver
Therapeutics
Exanthema
Neutropenia
Multiple Myeloma
Thrombocytopenia
Fatigue

ASJC Scopus subject areas

  • Hematology

Cite this

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. / Dispenzieri, Angela; Lacy, Martha; Zeldenrust, Steven R.; Hayman, Suzanne R.; Kumar, Shaji K; Geyer, Susan M.; Lust, John A.; Allred, Jacob B.; Witzig, Thomas Elmer; Rajkumar, S Vincent; Greipp, Philip R.; Russell, Stephen J; Kabat, Brian; Gertz, Morie.

In: Blood, Vol. 109, No. 2, 15.01.2007, p. 465-470.

Research output: Contribution to journalArticle

Dispenzieri, Angela ; Lacy, Martha ; Zeldenrust, Steven R. ; Hayman, Suzanne R. ; Kumar, Shaji K ; Geyer, Susan M. ; Lust, John A. ; Allred, Jacob B. ; Witzig, Thomas Elmer ; Rajkumar, S Vincent ; Greipp, Philip R. ; Russell, Stephen J ; Kabat, Brian ; Gertz, Morie. / The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. In: Blood. 2007 ; Vol. 109, No. 2. pp. 465-470.
@article{a9255f1e3681495982a4be1ee7f06e55,
title = "The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis",
abstract = "Primary systemic amyloidosis (AL) is an incurable plasma cell disorder. Lenalidomide, especially in conjunction with dexamethasone, is highly active in patients with multiple myeloma. We studied the toxicity and efficacy of lenalidomide in patients with AL. Patients with symptomatic AL, a measurable plasma cell disorder, and adequate hematologic and renal reserve were eligible. Patients received single-agent lenalidomide. If there was no evidence of progression after 3 months or of hematologic response after 3 cycles, dexamethasone was added. Twenty-three patients were enrolled. Thirteen were previously treated. Organ involvement was cardiac (64{\%}), renal (73{\%}), hepatic (23{\%}), and nerve (14{\%}). Within the first 3 cycles of therapy, 10 patients discontinued treatment: 4 early deaths, 3 adverse events, and 3 other causes. With a median follow-up of 17 months, 10 patients responded to treatment. In these patients, responses included 9 hematologic, 4 renal, 2 cardiac, and 2 hepatic. All but one of the responders had dexamethasone added to their treatment program. The most common grade 3 or 4 adverse events at least possibly attributable to lenalidomide were neutropenia (45{\%}), thrombocytopenia (27{\%}), rash (18{\%}), and fatigue (18{\%}). In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.",
author = "Angela Dispenzieri and Martha Lacy and Zeldenrust, {Steven R.} and Hayman, {Suzanne R.} and Kumar, {Shaji K} and Geyer, {Susan M.} and Lust, {John A.} and Allred, {Jacob B.} and Witzig, {Thomas Elmer} and Rajkumar, {S Vincent} and Greipp, {Philip R.} and Russell, {Stephen J} and Brian Kabat and Morie Gertz",
year = "2007",
month = "1",
day = "15",
doi = "10.1182/blood-2006-07-032987",
language = "English (US)",
volume = "109",
pages = "465--470",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

AU - Dispenzieri, Angela

AU - Lacy, Martha

AU - Zeldenrust, Steven R.

AU - Hayman, Suzanne R.

AU - Kumar, Shaji K

AU - Geyer, Susan M.

AU - Lust, John A.

AU - Allred, Jacob B.

AU - Witzig, Thomas Elmer

AU - Rajkumar, S Vincent

AU - Greipp, Philip R.

AU - Russell, Stephen J

AU - Kabat, Brian

AU - Gertz, Morie

PY - 2007/1/15

Y1 - 2007/1/15

N2 - Primary systemic amyloidosis (AL) is an incurable plasma cell disorder. Lenalidomide, especially in conjunction with dexamethasone, is highly active in patients with multiple myeloma. We studied the toxicity and efficacy of lenalidomide in patients with AL. Patients with symptomatic AL, a measurable plasma cell disorder, and adequate hematologic and renal reserve were eligible. Patients received single-agent lenalidomide. If there was no evidence of progression after 3 months or of hematologic response after 3 cycles, dexamethasone was added. Twenty-three patients were enrolled. Thirteen were previously treated. Organ involvement was cardiac (64%), renal (73%), hepatic (23%), and nerve (14%). Within the first 3 cycles of therapy, 10 patients discontinued treatment: 4 early deaths, 3 adverse events, and 3 other causes. With a median follow-up of 17 months, 10 patients responded to treatment. In these patients, responses included 9 hematologic, 4 renal, 2 cardiac, and 2 hepatic. All but one of the responders had dexamethasone added to their treatment program. The most common grade 3 or 4 adverse events at least possibly attributable to lenalidomide were neutropenia (45%), thrombocytopenia (27%), rash (18%), and fatigue (18%). In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.

AB - Primary systemic amyloidosis (AL) is an incurable plasma cell disorder. Lenalidomide, especially in conjunction with dexamethasone, is highly active in patients with multiple myeloma. We studied the toxicity and efficacy of lenalidomide in patients with AL. Patients with symptomatic AL, a measurable plasma cell disorder, and adequate hematologic and renal reserve were eligible. Patients received single-agent lenalidomide. If there was no evidence of progression after 3 months or of hematologic response after 3 cycles, dexamethasone was added. Twenty-three patients were enrolled. Thirteen were previously treated. Organ involvement was cardiac (64%), renal (73%), hepatic (23%), and nerve (14%). Within the first 3 cycles of therapy, 10 patients discontinued treatment: 4 early deaths, 3 adverse events, and 3 other causes. With a median follow-up of 17 months, 10 patients responded to treatment. In these patients, responses included 9 hematologic, 4 renal, 2 cardiac, and 2 hepatic. All but one of the responders had dexamethasone added to their treatment program. The most common grade 3 or 4 adverse events at least possibly attributable to lenalidomide were neutropenia (45%), thrombocytopenia (27%), rash (18%), and fatigue (18%). In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation.

UR - http://www.scopus.com/inward/record.url?scp=33846258025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846258025&partnerID=8YFLogxK

U2 - 10.1182/blood-2006-07-032987

DO - 10.1182/blood-2006-07-032987

M3 - Article

VL - 109

SP - 465

EP - 470

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -